ADPVAdaptiv Select ETF
The schedule
- Mon9Nov
(Driven by ROIV) The Q3 2026 earnings release will provide insight into the company's revenue performance and progress on its research and development initiatives. This event is critical for investors as it offers a snapshot of the company's operational and strategic achievements during the quarter. The release is expected to highlight key financial metrics and guidance that could influence market sentiment and stock valuation.
- Tue9Feb
(Driven by ROIV) The Q4 2026 earnings release will focus on the company's year-end performance and updates on its product pipeline. This event is essential for assessing the company's ability to meet its financial targets and progress in developing new treatments. Investors will be looking for clarity on revenue growth and the status of ongoing clinical trials.
- Mon10May
(Driven by ROIV) The Q1 2027 earnings release will emphasize new product launches and updates on clinical trial progress. This event is crucial for evaluating the company's innovation pipeline and its ability to translate research into commercial success. Investors will be closely monitoring revenue contributions from new products and the pace of trial advancements.
- Mon9Aug
(Driven by ROIV) The Q2 2027 earnings release will focus on revenue growth and key regulatory milestones. This event is vital for understanding the company's financial health and its progress in navigating the regulatory landscape. Investors will be interested in how the company is performing against its revenue goals and whether it has achieved any significant regulatory approvals.
- Fri29Oct
(Driven by BEN) Q3 2027 results.
Past
- Thu30Jul
Actual outcome: Bear
Intel reported a massive $11 billion GAAP net loss for Q2 2026, primarily driven by goodwill impairments. While free cash flow remained positive at $4.4 billion, the staggering loss and uncertainty surrounding Intel's capex and foundry updates weighed heavily on sector sentiment, dragging ADPV shares below the bear floor.
Intel reported a massive $11 billion GAAP net loss for Q2 2026, primarily driven by goodwill impairments. While free cash flow remained positive at $4.4 billion, the staggering loss and uncertainty surrounding Intel's capex and foundry updates weighed heavily on sector sentiment, dragging ADPV shares below the bear floor.